Peptides and methods using same for diagnosing and treating amyloid-associated diseases

• US 20040052928A1
• Filed: 09/06/2002
• Published: 03/18/2004
• Est. Priority Date: 09/06/2002
• Status: Abandoned Application

• Current Assignee: Tel Aviv University Future Technology Development L.P. (Tel Aviv University)
• Original Assignee: Tel Aviv University Future Technology Development L.P. (Tel Aviv University)
• Inventors: Gazit, Ehud
• Application Number:
  US10/235,852
• Publication Number:
  US 20040052928A1
• Time in Patent Office: Days
• US Class Current: 427/2.11
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4711 Alzheimer's disease; Amyloid plaque core protein
• CPC Class Codes: C07K 5/0819 with the first amino acid being acidic
• CPC Class Codes: C07K 5/1008 the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
• CPC Class Codes: C07K 5/1016 and aromatic or cycloaliphatic
• CPC Class Codes: C07K 5/1021 with the first amino acid being acidic

Abstract

A peptide comprising at least 5 amino acid residues and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth in SEQ ID NO: 7 as well as pharmaceutical compositions, kits and methods for diagnosing and treating amyloid associated diseases.

Claims

1. A peptide comprising at least 5 amino acid residues and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth in SEQ ID NO:

7.

2. The peptide of claim 1, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO:

4, 12 and 13.

3. The peptide of claim 1, wherein the peptide is as set forth in SEQ ID NO:

13.

4. The peptide of claim 1, wherein the peptide is as set forth in SEQ ID NO:

12.

5. The peptide of claim 1, further comprising at least two serine residues at a C-terminus thereof.

6. The peptide of claim 1, wherein the peptide is a linear or cyclic peptide.

7. A peptide comprising at least 5 amino acid residues and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth SEQ ID NO:

13, wherein the peptide is capable of forming self-aggregates under physiological conditions.

8. The peptide of claim 7, further comprising at least two serine residues at a C-terminus thereof.

9. The peptide of claim 7, wherein the peptide is a linear or cyclic peptide.

10. A peptide selected from the group consisting of SEQ ID NOs:

8, 9, 10 and 11.

11. The peptide of claim 10, wherein the peptide further includes at least two serine residues attached to a C-terminus thereof.

12. The peptide of claim 10, wherein the peptide is a linear or cyclic peptide.

13. A peptide having an amino acid sequence set forth in SEQ ID NO:

13.

14. The peptide of claim 13, further comprising at least two serine residues at a C-terminus thereof.

15. The peptide of claim 13, wherein the peptide is a linear or cyclic peptide.

16. A method of treating or preventing an amyloid-associated disease in an individual, the method comprising providing to the individual a therapeutically effective amount of a peptide having at least 5 amino acid residues and less than 15 amino acid residues, said peptide including an amino acid sequence as set forth in SEQ ID NO 7.

17. The method of claim 16, wherein said peptide is an active ingredient of a pharmaceutical composition which also includes a physiologically acceptable carrier.

18. The method of claim 16, wherein said peptide is expressed from a nucleic acid construct.

19. The method of claim 16, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO:

4, 12 and 13.

20. The method of claim 16, wherein said peptide is as set forth in SEQ ID NO. 13.

21. The method of claim 16, wherein said peptide is as set forth in SEQ ID NO:

12.

22. The method of claim 16, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

23. The method of claim 16, wherein said peptide is a linear or cyclic peptide.

24. A method of treating or preventing an amyloid-associated disease in an individual, the method comprising providing to the individual therapeutically effective amount of a peptide having at least 5 amino acid residues and less than 15 amino acid residues, said peptide including an amino acid sequence as set forth in SEQ ID NO:

13 and being capable of self aggregating under physiological conditions.

25. The method of claim 24, wherein said peptide is an active ingredient of a pharmaceutical composition, which also includes a physiologically acceptable carrier.

26. The method of claim 24, wherein said peptide is expressed from a nucleic acid construct.

27. The method of claim 24, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

28. The method of claim 24, wherein said peptide is a linear or cyclic peptide.

29. A method of treating or preventing an amyloid-associated disease in an individual, the method comprising providing to the individual a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NOs:

8, 9, 10 and 11, wherein said peptide is an active ingredient of a pharmaceutical compositions which also includes a physiologically acceptable carrier.

30. The method of claim 29, wherein said peptide is an active ingredient of a pharmaceutical composition, which also includes a physiologically acceptable carrier.

31. The method of claim 29, wherein said peptide is expressed from a nucleic acid construct.

32. The method of claim 29, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

33. The method of claim 29, wherein said peptide is a linear or cyclic peptide.

34. A method of treating or preventing an amyloid-associated disease in an individual, the method comprising providing to the individual a therapeutically effective amount of a peptide having the amino acid sequence set forth in SEQ ID NO:

13 wherein said peptide is an active ingredient of a pharmaceutical compositions which also includes a physiologically acceptable carrier.

35. The method of claim 34, wherein said peptide is an active ingredient of a pharmaceutical composition, which also includes a physiologically acceptable carrier.

36. The method of claim 34, wherein said peptide is expressed from a nucleic acid construct

37. The method of claim 34, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

38. A pharmaceutical composition for treating or preventing an amyloid-associated disease comprising as an active ingredient a peptide having at least 5 amino acid residues and less than 15 amino acid residues, said peptide including an amino acid sequence as set forth in SEQ ID NO:

7 and a pharmaceutically acceptable carrier or diluent.

39. The pharmaceutical composition of claim 38, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO:

4, 12 and 13.

40. The pharmaceutical composition of claim 38, wherein said peptide is as set forth in SEQ ID NO:

13.

41. The pharmaceutical composition of claim 38, wherein said peptide is as set forth in SEQ ID NO:

12.

42. The pharmaceutical composition of claim 38, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

43. The pharmaceutical composition of claim 38, wherein said peptide is a linear or cyclic peptide.

44. A pharmaceutical composition for treating or preventing an amyloid-associated disease comprising as an active ingredient a peptide selected from the group consisting of SEQ ID NOs:

8, 9, 10 and 11 and a pharmaceutically acceptable carrier or diluent.

45. The pharmaceutical composition of claim 44, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

46. The pharmaceutical composition of claim 44, wherein said linear or cyclic peptide.

47. A pharmaceutical composition for treating or preventing an amyloid-associated disease comprising as an active ingredient a peptide having the amino acid sequence set forth in SEQ ID NO:

13 and a pharmaceutically acceptable carrier or diluent.

48. The pharmaceutical composition of claim 47, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

49. The pharmaceutical composition of claim 47, wherein said peptide is a linear or cyclic peptide.

50. A nucleic acid construct comprising a polynucleotide segment encoding a peptide selected from the group consisting of SEQ ID NOs:

8, 9, 10 and 11.

51. The nucleic acid construct of claim 50 further comprising a promoter.

52. The nucleic acid construct of claim 50, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

53. A nucleic acid construct comprising a polynucleotide segment encoding a peptide having the amino acid sequence set forth in SEQ ID NO. 13.

54. The nucleic acid construct of claim 53 further comprising a promoter.

55. The nucleic acid construct of claim 53, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

56. A nucleic acid construct comprising a polynucleotide segment encoding a peptide having at least 5 amino acid residues and less than 15 amino acid residues, said peptide including an amino acid sequence as set forth in SEQ ID NO:

7

57. The nucleic acid construct of claim 56 further comprising a promoter.

58. The nucleic acid construct of claim 56, wherein said peptide further includes at least two serine residues attached to a C-terminus thereof.

59. The nucleic acid construct of claim 56, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO:

4, 12 and 13.

60. The nucleic acid construct of claim 56, wherein said peptide is as set forth in SEQ ID NO:

13.

61. The nucleic acid construct of claim 56, wherein said peptide is as set forth in SEQ ID NO:

12.